The University of Hyderabad (UoH), a premier Institution of Post graduate teaching and research enters into an MoU with NATCO PHAMA Limited, Hyderabad engaged in Pharmaceutical Research & Development activities, for carrying out advance research in the areas of pharmaceutical importance particularly, discovery of novel drugs as well as development of novel drug delivery systems viz., nano formulations of new chemical entities and novel biotechnological processes for specific products with potential commercial importance.


The parties will promote cooperation in academic exchange, R & D collaborations, training and research in the areas of Biotechnology, Pharmacology, Toxicology, Pharmaceutical technology, and organisation of national and international symposia, conferences, specialized exhibition and similar events in areas of mutual interest.


The MoU was signed on 21st March 2017 by Shri Chowdary V Nannapaneni, Chairman and Managing Director of Natco Pharma Ltd. And Shri P Sardar Singh, Registrar of UoH in the presence of Prof. Appa Rao Podile, Vice Chancellor, Prof. B P Sanjay, Pro Vice Chancellor, Prof. P Reddanna, Dean-School of Life Sciences, Prof. Nirmal Viswanathan, Coordinator –R & D of UoH and other officials. The School of Life Sciences, UoH has been undertaking collaborative research in the areas of Drug discovery for the past several years with Natco Pharma, which has resulted in developing one of the molecules to Phase-II clinical trials for the treatment of chronic myeloid leukaemia.


This MoU is being entered to further strengthen collaborative research programme in the areas specified above at a larger scale. The School of Life Sciences, one of the largest in the country with about 55 Faculty members, 350 Ph.D. scholars and 60 post docs, is well equipped with the state-of-art infrastructural facilities viz., Genomics, Proteomics and Metabolomics, Image technologies. The School is actively engaged in research on infectious diseases (viral, bacterial, protozoan), and inflammatory disorders including cancer.


This MoU signed for a period of five years will foster the academy – industry interactions by utilisation of expertise of the faculty and the infrastructural facilities for promoting anti cancer drug discovery research and development at Natco Pharma.